INSUBCONTINENT EXCLUSIVE:
leading journals of immunology.Ranked first in the world for citing immunology, the journal is ranked Q1 and published as open access, in
Fallah Mehrabadi.In this article, how to achieve the injectable dose and also the high immunogenicity of the vaccine are specified.The
article will be published online next week and will be available in all regions of the world.The results of phases one, two, and three of
the vaccine will also be published in the most prestigious journals of the world in the coming months.Developed by the Razi Vaccine and
Serum Research Institute, Razi Cov Pars is the second Iranian-made vaccine that started the clinical trial on February 27, 2021.The vaccine
is protein-based, which employs recombinant versions of the spike protein and tutors the immune system against the virus by producing
antibodies.It is developed in 3 doses
The first two doses are injectable and the third dose is intranasal
The second dose of the vaccine will be injected into the volunteers 21 days later and the third dose will be inhaled 51 days later.At the
end of the second phase of clinical trials, Cov Pars proved 80 percent immunogenicity.A number of countries have requested to purchase the
Cov Pars vaccine for COVID-19, and negotiations are underway to take the necessary measures for export, Mohammad Hossein Fallah, spokesman
for the Razi Vaccine and Serum Research Institute said in December 2021.So far, three Iranian vaccines against coronavirus published the
results of their clinical studies in prestigious journals.An article on the first two clinical trial phases of COVIRAN - the first homegrown
trial has been accepted by a prestigious international scientific journal, to be soon published, Alireza Biglari, head of the Pasteur
based on adenovirus, have been published in one of the prestigious international journals.FB/MG
